1. Yang, J.D. and J.K. Heimbach, New advances in the diagnosis and management of hepatocellular carcinoma. Bmj, 2020: p. m3544.
2. Couri, T. and A. Pillai, Goals and targets for personalized therapy for HCC. Hepatology International, 2019. 13(2): p. 125-137.
3. Debes, J., et al., Serum Biomarkers for the Prediction of Hepatocellular Carcinoma. Cancers, 2021. 13(7): p. 1681.
4. Wiley SR, S.K., Smolak PJ, Din WS, Huang CP, Nicholl JK, et al., <Identification and characterization of a new member of the TNF family that induces apoptosis .pdf>. Immunity, 1995. 3: p. 673-82.
5. Walczak H, M.R., Ariail K, Gliniak B, Griffith TS, Kubin M, et al., Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med, 1995. 5: p. 157-63.
6. Ashkenazi A, P.R., Fong S, Leung S, Lawrence DA, Marsters SA, and e. al., Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999. 104: p. 155-62.
7. Wong, S.H.M., et al., The TRAIL to cancer therapy: Hindrances and potential solutions. Critical Reviews in Oncology/Hematology, 2019. 143: p. 81-94.
8. de Miguel, D., et al., Onto better TRAILs for cancer treatment. Cell Death & Differentiation, 2016. 23(5): p. 733-747.
9. Stuckey, D.W. and K. Shah, TRAIL on trial: preclinical advances in cancer therapy. Trends in Molecular Medicine, 2013. 19(11): p. 685-694.
10. O'Leary, L., et al., Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. Oncogene, 2015. 35(10): p. 1261-1270.
11. Zhang, L. and B. Fang, Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Therapy, 2004. 12(3): p. 228-237.
12. Fulda, S. and K.M. Debatin, Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene, 2006. 25(34): p. 4798-4811.
13. Czabotar, P.E., et al., Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nature Reviews Molecular Cell Biology, 2013. 15(1): p. 49-63.
14. Han, L., et al., Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy. Journal of Experimental & Clinical Cancer Research, 2019. 38(1).
15. Jo, E.B., et al., Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells. BMC Cancer, 2019. 19(1).
16. Lee, H., et al., Ginsenoside Rh2 epigenetically regulates cell-mediated immune pathway to inhibit proliferation of MCF-7 breast cancer cells. Journal of Ginseng Research, 2018. 42(4): p. 455-462.
17. Wang, Z., et al., Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia. Signal Transduction and Targeted Therapy, 2020. 5(1).
18. Oh, J., et al., Caspase-3-dependent protein kinase C delta activity is required for the progression of Ginsenoside-Rh2-induced apoptosis in SK-HEP-1 cells. Cancer Letters, 2005. 230(2): p. 228-238.
19. Nag, S.A., Ginsenosides as anticancer agents: In vitro and in vivo activities, structure–activity relationships, and molecular mechanisms of action. Frontiers in Pharmacology, 2012. 3.
20. S, H., et al., Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through targeting IL-6-induced JAK2/STAT3 pathway in human colorectal cancer cells. Journal of ethnopharmacology, 2016. 194: p. 83-90.
21. Shi, Q., et al., Anticancer effect of 20(S)-ginsenoside Rh2 on HepG2 liver carcinoma cells: Activating GSK-3β and degrading β-catenin. Oncology Reports, 2016. 36(4): p. 2059-2070.
22. Zhu C, L.F., Qian W, Zhang T, Li F., Combined Effect of Sodium Selenite and Ginsenoside Rh2 on HCT116 Human Colorectal Carcinoma Cells. Arch Iran Med, 2016. 19(1): p. 23-29.
23. Lee, J.-Y., et al., Sensitization of TRAIL-Induced Cell Death by 20(S)-Ginsenoside Rg3 via CHOP-Mediated DR5 Upregulation in Human Hepatocellular Carcinoma Cells. Molecular Cancer Therapeutics, 2013. 12(3): p. 274-285.
24. Kelley, S., Targeting death receptors in cancer with Apo2L/TRAIL. Current Opinion in Pharmacology, 2004. 4(4): p. 333-339.
25. Jeon, M.-Y., et al., Dexamethasone Inhibits TRAIL-Induced Apoptosis through c-FLIP(L) Upregulation and DR5 Downregulation by GSK3β Activation in Cancer Cells. Cancers, 2020. 12(10): p. 2901.
26. Woo, S.M., K.-j. Min, and T.K. Kwon, Magnolol Enhances the Therapeutic Effects of TRAIL through DR5 Upregulation and Downregulation of c-FLIP and Mcl-1 Proteins in Cancer Cells. Molecules, 2020. 25(19): p. 4591.
27. Rasheduzzaman, M., et al., Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux. The International Journal of Biochemistry & Cell Biology, 2018. 102: p. 20-30.
28. Wu, B., et al., Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission. Archives of Biochemistry and Biophysics, 2020. 692: p. 108539.
29. Shi, Y., et al., Oxidative stress-driven DR5 upregulation restores TRAIL/Apo2L sensitivity induced by iron oxide nanoparticles in colorectal cancer. Biomaterials, 2020. 233: p. 119753.
30. Wang, X. and Y. Wang, Ginsenoside Rh2 Mitigates Pediatric Leukemia Through Suppression of Bcl-2 in Leukemia Cells. Cellular Physiology and Biochemistry, 2015. 37(2): p. 641-650.
31. Saraei, R., et al., The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia. Biomedicine & Pharmacotherapy, 2018. 107: p. 1010-1019.